title: Histopathological analysis of retinopathy of prematurity after intravitreal bevacizumab.
abstract: We report the case of a premature infant with end-organ failure who developed high-risk retinopathy of prematurity (ROP) bilaterally and was treated with intravitreal bevacizumab (IVB) injection therapy with regression noted on follow-up clinical examination. The infant died 3 weeks after IVB injection therapy. Histopathological analysis was conducted on bilateral globes and revealed persistent preretinal vessels.
authors.affiliation: Medical College of Wisconsin, The Eye Institute, Milwaukee, Wisconsin.
authors.forename: Carson R
authors.initials: CR
authors.lastname: Bee
authors.affiliation: University of Wisconsin, Madison, Wisconsin.
authors.forename: Christopher K H
authors.initials: CKH
authors.lastname: Burris
authors.affiliation: University of Wisconsin, Madison, Wisconsin.
authors.forename: Heather A D
authors.initials: HAD
authors.lastname: Potter
authors.affiliation: University of Wisconsin, Madison, Wisconsin.
authors.forename: Devasis
authors.initials: D
authors.lastname: Reddy
authors.affiliation: Medical College of Wisconsin, The Eye Institute, Milwaukee, Wisconsin.
authors.forename: Kenneth B
authors.initials: KB
authors.lastname: Simons
authors.affiliation: Medical College of Wisconsin, The Eye Institute, Milwaukee, Wisconsin. Electronic address: dcostakos@mcw.edu.
authors.forename: Deborah M
authors.initials: DM
authors.lastname: Costakos
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000068258:Bevacizumab / Q000008:administration & dosage*; D049109:Cell Proliferation; D004730:Endothelium, Vascular / Q000473:pathology; D017809:Fatal Outcome; D006801:Humans; D007223:Infant; D007234:Infant, Premature; D058449:Intravitreal Injections; D017075:Laser Coagulation; D008297:Male; D009102:Multiple Organ Failure / Q000150:complications; D012160:Retina / Q000473:pathology*; D012178:Retinopathy of Prematurity / Q000150:complications / Q000473:pathology* / Q000628:therapy; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab